Vaxcyte is a biopharma startup founded in 2013 in the United States. The company's mission is to engineer high-fidelity vaccines to combat bacterial diseases. Its flagship product, VAX-24, is a broad-spectrum pneumococcal conjugate vaccine with 24 valences, developed to prevent invasive pneumococcal disease. Vaxcyte stands out with its innovative approach, utilizing modern synthetic techniques and the XpressCFᵀᴹ cell-free protein synthesis platform, licensed from Sutro Biopharma, Inc. The company's pipeline includes VAX-XP, a pneumococcal conjugate vaccine with expanded coverage, VAX-A1 for preventing Group A Strep infections, and VAX-PG to slow or stop the progression of periodontal disease. Vaxcyte aims to address the significant health and economic impact of invasive bacterial infections. In January 2024, the company received a notable $862.50MPost-IPO equity investment, signifying investor confidence in its work. With its innovative technology and strong investment support, Vaxcyte is poised to make a significant impact in the fight against bacterial diseases.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $862.50M | - | 30 Jan 2024 | |
| Post-IPO Equity | $500.00M | - | 19 Apr 2023 | |
| Post-IPO Equity | $600.00M | - | 26 Oct 2022 | |
| Post-IPO Equity | $100.00M | - | 13 Jan 2022 | |
| Grant | $3.20M | 1 |
|
05 Aug 2021 |
We care about your data, and we'd love to use cookies make your experience better.
